药物对胰岛素抵抗、PPARγ影响的研究进展

Research Progresses of Drugs on Insulin Resistance and PPARγ

糖尿病是世界上最常见的人类疾病之一,发病率高。近年来在中国其发病率逐年增加。胰岛素抵抗是2裂糖尿病处于糖尿病前期阶段表现出的异常状态。过氧化物酶体增殖物活化受体-γ(PPARγ)属于核转录因子激素受体超家族成员之一,它在脂肪分化及2型糖尿病发展中起关键作用。随着对胰岛素增敏剂噻唑烷二酮(TZD)类药物作用机制的深入研究,发现PARγ是该类药物的主要功能受体。因此,关于PPARγ与胰岛素抵抗之间关系的研究日趋热门化。文章就近年来胰岛素抵抗与PPARγ以及约物治疗研究进展作一综述。

Diabetes,one of the most common human diseases in the world, has a high morbitity. And the incidence has been increasing m Chinese recently. Insulin resistance is the antecedent abnormality in the early prediabetic state of type 2 diabetes mellitus （2-DM）. Peroxisome proliferator-activated receptor-γ, （PPARγ） is a member of the hormone receptor superfamily of nuclear transcription factors. It plays a critical role in adipocyte differentiation and the development of type 2 diabetes mellitus. With the deep research of mechanism of action of thiazolidinediones （TZDs） which are able to improve insulin sensitivity, people found that PPARγ, is the main functional factor of these drugs. Accordingly, studies on the relations between insulin resistance and PPARγ have became hotter. This is a review about the research progress recently of insulin resistance, PPARγ and drug therapies relative.